BioLife Solutions, Inc. (BLFS)
| Market Cap | 498.74M |
| Revenue (ttm) | 138.53M |
| Net Income (ttm) | -13.58M |
| Shares Out | 42.41M |
| EPS (ttm) | -0.20 |
| PE Ratio | n/a |
| Forward PE | 666.67 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 140,490 |
| Open | 12.50 |
| Previous Close | 12.76 |
| Day's Range | 11.76 - 12.73 |
| 52-Week Range | 10.40 - 60.67 |
| Beta | 1.75 |
| Analysts | Buy |
| Price Target | 47.30 (+302.2%) |
| Earnings Date | May 9, 2022 |
About BLFS
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for BLFS stock is "Buy." The 12-month stock price forecast is 47.3, which is an increase of 302.21% from the latest price.
News
BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Lags Revenue Estimates
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of 29.17% and 4.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
BioLife Solutions Reports First Quarter 2022 Financial Results
Revenue of $36.2 million increased 115% over Q1 2021, with organic revenue growth of 45% and biopreservation media revenue growth of 53% Affirms 2022 revenue guidance of $159.5 million to $171.0 million...
BioLife Solutions Executes Co-Marketing Agreement with Coriell Institute for Medical Research to Offer Biostorage, Bi...
BOTHELL, Wash. , May 9, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and bro...
BioLife Solutions to Report First Quarter 2022 Financial Results and Provide Business Update on May 9, 2022
BOTHELL, Wash. , May 2, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and bro...
New Strong Sell Stocks for May 2nd
ALEC, AMRS, and BLFS have been added to the Zacks Rank #5 (Strong Sell) List on May 2, 2022
BioLife Solutions, Inc. Announces Change of Auditor to Grant Thornton LLP
BOTHELL, Wash. , April 7, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services...
New Strong Sell Stocks for March 31st
BLFS, CRNT, and AMBA have been added to the Zacks Rank #5 (Strong Sell) List on March 31, 2022.
BioLife Solutions Receives Nasdaq Notice of Noncompliance for Delayed 10-K Filing
BOTHELL, Wash. , March 18, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and service...
BioLife Solutions Announces Additional Delay in Filing of Annual Report on Form 10-K
BOTHELL, Wash., March 17, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services...
BioLife Solutions Secures Strategic Customer Wins and Plans 2022 Expansion in $400 Million Biostorage Services Market
BOTHELL, Wash. , March 15, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and ...
BioLife Solutions to Attend and Present at Upcoming Investor Conferences
BOTHELL, Wash., March 1, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services ...
BioLife Solutions, Inc. (BLFS) Reports Q4 Loss, Tops Revenue Estimates
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -131.25% and 0.06%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
BioLife Solutions Reports Unaudited Fourth Quarter and Full Year 2021 Financial Results
BOTHELL, Wash. , Feb. 28, 2022 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and servic...
BioLife Solutions to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on Februa...
BOTHELL, Wash., Feb. 21, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and b...
PETQ or BLFS: Which Is the Better Value Stock Right Now?
PETQ vs. BLFS: Which Stock Is the Better Value Option?
BioLife Sciences Inc. (OTC Markets: BLFE) Announced Today That the Company Has Finalized a Definitive Agreement With ...
Henderson, Nevada, Feb. 01, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioLife Sciences (OTCPK: BLFE) is pleased to announce that it has finalized a definitive agreement (the “Agreement”) with Health ...
Best Biotech Stocks to Invest in Now
Try your hand at morphing science and business for a great investment opportunity in biotech.
BioLife Solutions Announces Preliminary 2021 Revenue of $119 Million, Up 148% Over 2020
BOTHELL, Wash., Jan. 10, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy (CGT) and broade...
BioLife Solutions Collaborates with Seattle Children's to Improve Viral Vector and Cell and Gene Therapy Manufacturing
BOTHELL, Wash., Jan. 4, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy and broader bioph...
UNICEF Selects Ultra-Low Temperature (ULT) Freezers from BioLife Solutions to Extend Thermal Stability of COVID-19 Va...
BOTHELL, Wash., Dec. 16, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and br...
BioLife Solutions Ranks 353 Among Fastest-Growing Companies in North America on the 2021 Deloitte Technology Fast 500™
BOTHELL, Wash., Nov. 17, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and b...
BioLife Solutions Named to Inc. Magazine Inaugural List of Best-Led Companies
BOTHELL, Wash., Nov. 15, 2021 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and service...
BioLife Solutions Announces Third Quarter 2021 Financial Results
BOTHELL, Wash., Nov. 11, 2021 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and service...
BioLife Solutions Announces Executive Management Changes
BOTHELL, Wash., Nov. 4, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (the "Company") (Nasdaq: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies...
BioLife Solutions to Report Third Quarter 2021 Financial Results and Provide Business Update on November 11, 2021
BOTHELL, Wash., Nov. 4, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and bro...